BIOMAT Database Logo BIOMAT Database Logo

[Clinical experiences with radiotherapy and ICRF 159 in sarcomas]. 1978

W Rhomberg, and E Mesche, and D Gefeller, and E Hassenstein

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D011929 Razoxane An antimitotic agent with immunosuppressive properties. ICRF-159,ICRF-186,NSC-129943,Razoxane Mesylate, (R)-Isomer,Razoxane, (R)-Isomer,Razoxin,ICRF 159,ICRF 186,ICRF159,ICRF186,NSC 129943,NSC129943
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

W Rhomberg, and E Mesche, and D Gefeller, and E Hassenstein
Radiotherapy and ICRF 159 in the treatment of soft tissue sarcomas.
January 1978, International journal of radiation oncology, biology, physics,
W Rhomberg, and E Mesche, and D Gefeller, and E Hassenstein
Radiotherapy combined with ICRF 159 (NSC 129943).
January 1978, International journal of radiation oncology, biology, physics,
W Rhomberg, and E Mesche, and D Gefeller, and E Hassenstein
Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.
January 1978, Cancer,
W Rhomberg, and E Mesche, and D Gefeller, and E Hassenstein
Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas.
August 1982, American journal of clinical oncology,
W Rhomberg, and E Mesche, and D Gefeller, and E Hassenstein
Combination of radiotherapy and razoxane (ICRF 159) for chondrosarcoma.
September 1979, Cancer,
W Rhomberg, and E Mesche, and D Gefeller, and E Hassenstein
Combined treatment of the Walker tumour with radiotherapy and ICRF 159.
January 1974, Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology,
W Rhomberg, and E Mesche, and D Gefeller, and E Hassenstein
ICRF-159: current status and clinical prospects.
November 1977, European journal of cancer,
W Rhomberg, and E Mesche, and D Gefeller, and E Hassenstein
Editoral: ICRF 159.
March 1974, Lancet (London, England),
W Rhomberg, and E Mesche, and D Gefeller, and E Hassenstein
Letter: ICRF 159.
May 1974, Lancet (London, England),
W Rhomberg, and E Mesche, and D Gefeller, and E Hassenstein
Letter: ICRF 159.
March 1974, Lancet (London, England),
Copied contents to your clipboard!